AbCellera Biologics downgraded by The Benchmark Company
$ABCL
Pharmaceuticals and Biotechnology
Health Care
The Benchmark Company downgraded AbCellera Biologics from Buy to Hold
Get the next $ABCL alert in real time by email
Get the next $ABCL alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ABCL
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2024 | Buy → Hold | The Benchmark Company | |
| 2/22/2024 | $9.00 | Hold → Buy | The Benchmark Company |
| 12/5/2023 | $6.00 | Overweight | KeyBanc Capital Markets |
| 11/6/2023 | Buy → Hold | The Benchmark Company | |
| 10/13/2023 | $20.00 | Overweight | Piper Sandler |
| 2/28/2023 | Outperform | Cowen | |
| 12/15/2022 | $30.00 | Buy | Goldman |
| 11/16/2022 | $29.00 | Buy | Truist |
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
AbCellera (NASDAQ:ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
AbCellera (NASDAQ:ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting, to be held April 25 to 30 at the McCormick Place Convention Center in Chicago, Illinois. Details on AbCellera's poster presentation at AACR are as follows: Title: PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer Abstract Number: 6012 Session: Therapeutic Antibodies, Including Engineered Antibodies 2 Date and Time: Tuesday, April 29, from 2:00 p.m. to 5:00 p.m. CDT Location: Section 35, Board 7 About AbCellera's T-Cell Engager Pl
AbCellera Reports Full Year 2024 Business Results
AbCellera (NASDAQ:ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and completing significant investments in our capabilities. We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "As a result, we enter 2025 on track to initiate Phase 1 clinical trials for our first two programs, ABCL635
AbCellera Biologics downgraded by The Benchmark Company
The Benchmark Company downgraded AbCellera Biologics from Buy to Hold
AbCellera Biologics upgraded by The Benchmark Company with a new price target
The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $9.00
KeyBanc Capital Markets initiated coverage on AbCellera Biologics with a new price target
KeyBanc Capital Markets initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $6.00
Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
SEC Form S-3ASR filed by AbCellera Biologics Inc.
S-3ASR - AbCellera Biologics Inc. (0001703057) (Filer)
SEC Form S-8 filed by AbCellera Biologics Inc.
S-8 - AbCellera Biologics Inc. (0001703057) (Filer)
SEC Form 10-K filed by AbCellera Biologics Inc.
10-K - AbCellera Biologics Inc. (0001703057) (Filer)
AbCellera Announces Resignation of Board Member
AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir
DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer
TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev
AbCellera Announces Changes to Its Board of Directors
AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
AbCellera (NASDAQ:ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data
AbCellera Reports Full Year 2024 Business Results
AbCellera (NASDAQ:ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and completing significant investments in our capabilities. We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "As a result, we enter 2025 on track to initiate Phase 1 clinical trials for our first two programs, ABCL635
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
AbCellera (NASDAQ:ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, da
Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.
SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)
SEC Form SC 13G filed by AbCellera Biologics Inc.
SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)
SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)
SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)